Pascale Cony‐Makhoul

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 405 citations · Full text

Roots of Clinical Resistance to STI-571 Cancer Therapy

Christophe Barthe, Pascale Cony‐Makhoul, Junia V. Melo et al. · Science · 2001 · 276 citations

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Treatment Resistance +18

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

Gandhi Damaj, Rémy Gressin, Krimo Bouabdallah et al. · Journal of Clinical Oncology · 2012 · 160 citations · Full text

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret et al. · Leukemia · 2015 · 120 citations · Full text

Hematological Malignancy, Transfusion Medicine, Hematology +4

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini, Stéphanie Dulucq, Lisa Boureau et al. · Clinical Cancer Research · 2019 · 108 citations · Full text